Overview

• Hours after President Trump’s new Major’s List to Congress, the U.S. Embassy in New Delhi said it revoked and denied visas for certain Indian business leaders over alleged fentanyl precursor trafficking.
• The embassy cited Immigration and Nationality Act sections 221(i), 212(a)(2)(C), and 214(b), noting the actions may also render close family members ineligible for U.S. travel.
• Executives connected to companies known to have trafficked precursors will be flagged for heightened scrutiny in future U.S. visa applications, the embassy said.
• The announcement did not identify affected individuals or firms and thanked the Indian government for cooperation, with Chargé d’affaires Jorgan Andrews warning of consequences for traffickers.
• Trump’s determination named 23 countries as major drug transit or producing nations, with five labeled as having failed demonstrably, and the embassy action builds on earlier DOJ cases involving India-based Raxuter Chemicals, Athos Chemicals, and executive Bhavesh Lathiya.